Legend Biotech

$54.44 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). It is also developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL. The Company also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.

Stock Analysis

last close $52.61
1-mo return 23.1%
3-mo return 46.7%
avg daily vol. 670.7T
52-week high 58
52-week low 30.76
market cap. $8.2B
forward pe -
annual div. -
roe -107.5%
ltg forecast -
dividend yield -
annual rev. $748M
inst own. 33.9%

Subscribe now for daily local and international financial news